查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965452

惡性黑色素瘤診斷和治療市場－全球產業規模、佔有率、趨勢、機會和預測：按產品類型、治療藥物、地區和競爭格局分類，2021-2031年

Melanoma Diagnostics and Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Therapeutics, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球黑色素瘤診斷和治療市場預計將從 2025 年的 76.6 億美元成長到 2031 年的 138.1 億美元，複合年成長率為 10.32%。

該市場涵蓋切片檢查和皮膚鏡檢查等篩檢調查方法，以及標靶治療和免疫療法等藥物干預措施。推動市場成長的主要因素是全球惡性皮膚癌發生率的上升和人口老化。此外，加強對紫外線風險和皮膚檢測的公共衛生宣傳活動也促進了對早期檢測服務的需求。根據美國癌症協會預測，到2025年，美國預計將新增約104,960例侵襲性黑色素瘤病例。

市場概覽
預測期 2027-2031
市場規模：2025年 76.6億美元
市場規模：2031年 138.1億美元
複合年成長率：2026-2031年 10.32%
成長最快的細分市場 免疫療法
最大的市場 北美洲

阻礙市場發展的最大障礙之一是現代療法的高昂費用。免疫療法和生物製藥的高價給醫療預算帶來了沉重負擔，並使不同地區的報銷流程變得複雜。這些經濟障礙限制了患者獲得必要治療的機會，並阻礙了開發中國家，其中很大一部分醫療費用由患者承擔。

市場促進因素

全球皮膚癌和惡性黑色素瘤發生率的上升是診斷和治療領域發展的主要驅動力。疾病盛行率的上升需要先進的篩檢技術和有效的藥物療法，從而擴大了患者群體。由於人口老化和環境因素導致病例增加，醫療保健系統正優先考慮早期檢測措施以降低死亡風險，這也持續推高了對診斷工具的需求。正如世界衛生組織（WHO）國際癌症研究機構（IARC）於2024年2月發布的《全球癌症負擔》報告所述，2022年全球約有33萬例新增惡性黑色素瘤病例。此趨勢在高風險地區尤其顯著；例如，英國癌症研究中心於2024年5月發表的題為《皮膚癌病例數創歷史新高》的分析報告預測，2024年英國新增黑色素瘤病例將達到創紀錄的20800例。

同時，查核點抑制劑和新型免疫療法的快速發展正在推動市場收入成長，並改變臨床通訊協定。從傳統化療轉向精準免疫腫瘤藥物正在提高存活率，並加速這些生物療法的廣泛商業性化應用。領先的製藥公司正從這些創新中獲得豐厚的經濟回報，從而推動聯合治療的持續研發。根據默克公司於2024年2月發布的《2023年第四季及全年財務業績報告》，Keytruda的年銷售額成長19%，達到250億美元，主要得益於對黑色素瘤等轉移性疾病的需求。這項財務成功凸顯了市場對下一代治療藥物在未來價值創造方面的高度依賴。

市場挑戰

新療法，尤其是免疫療法和生物製藥，高成本是全球黑色素瘤診斷和治療市場的主要阻礙因素。儘管這些治療方法通常能帶來卓越的臨床療效，但其高昂的價格卻對私人保險公司和醫療保健系統造成了沉重的經濟負擔。這種經濟壓力往往導致嚴格的報銷政策和延長核准週期，從而延緩了這些藥物在價格敏感型市場中的商業性化應用。因此，高昂的經濟障礙降低了處方量，並直接限制了製藥研發公司的獲利能力。

全球醫療保健資金籌措方面的差異加劇了定價問題，限制了那些嚴重依賴自費支付的地區採用先進療法。根據美國臨床腫瘤學會（ASCO）統計，2024年用於治療轉移性黑色素瘤的某些查核點抑制劑的每月費用約為47,538美元。對於許多患者和小規模保險計劃而言，這些費用難以承受，導致先進療法的普及潛力與其可及性之間存在巨大差距。這最終阻礙了整體市場成長。

市場趨勢

腫瘤浸潤淋巴細胞 (TIL) 療法的日益普及，標誌著進行性和難治性固態腫瘤的治療正朝著個人化細胞機制的方向發生重大轉變。這一趨勢滿足了接受標準抗 PD-1 療法後病情進展患者的迫切需求，也標誌著治療重點從一般免疫刺激轉向精準的細胞標靶治療。首個獲得 FDA核准的TIL 產品迅速取得商業性成功，凸顯了複雜生物製藥在轉移性疾病治療中極高的市場接受度。根據 Iovance Biotherapeutics 公司於 2024 年 11 月發布的“2024 年第三季及全年財務業績”，該公司僅在第三季度就憑藉 Amtagvi 在美國的銷售實現了 4,210 萬美元的淨產品收入。

同時，基於mRNA的個人化癌症疫苗的研發正在利用旨在降低復發率的新型抗原序列，革新輔助性治療。這些治療方法旨在識別患者特異性的腫瘤突變譜，並與已證實有效的查核點抑制劑合併使用，可誘導強效且個人化的T細胞反應。與術後標準單藥治療相比，此策略顯著改善了患者的長期存活前景。根據默克公司2024年6月發布的公告“Moderna和默克公佈mRNA-4157聯合Pembrolizumab聯合治療的3年新數據”，在III/IV期高危險群黑色素瘤患者中，mRNA-4157疫苗聯合Pembrolizumab珠單抗（Keytruda）的聯合治療與帕博利珠單抗或治療單劑復發

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：惡性黑色素瘤診斷與治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類型（診斷性皮膚鏡設備、切片檢查設備）
    • 依治療方法（化療、生物療法、標靶治療、免疫療法）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美惡性黑色素瘤診斷與治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲惡性黑色素瘤診斷與治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區惡性黑色素瘤診斷與治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲惡性黑色素瘤診斷和治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲惡性黑色素瘤診斷與治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球惡性黑色素瘤診斷與治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Inc.
  • Amgen, Inc.
  • Bristol-Myers Squibb
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies Inc.
  • AstraZeneca Plc
  • Pfizer Inc.
  • Eli Lilly & Co.
  • GlaxoSmithKline Plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23754

The Global Melanoma Diagnostics and Therapeutics Market is projected to expand from a valuation of USD 7.66 Billion in 2025 to USD 13.81 Billion by 2031, reflecting a CAGR of 10.32%. This market encompasses screening methodologies, including biopsies and dermatoscopy, alongside pharmacological interventions such as targeted therapies and immunotherapies. Growth is primarily driven by the rising global prevalence of malignant skin cancers and an aging population. Additionally, heightened public health campaigns focusing on ultraviolet radiation risks and skin examinations are sustaining the demand for early detection services. As reported by the American Cancer Society, approximately 104,960 new invasive melanoma cases are expected to be diagnosed in the United States in 2025.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.66 Billion
Market Size 2031USD 13.81 Billion
CAGR 2026-203110.32%
Fastest Growing SegmentImmune Therapy
Largest MarketNorth America

One significant obstacle hindering market progression is the exorbitant cost associated with modern therapeutic agents. The high price points for immunotherapies and biologics impose substantial pressure on healthcare budgets, complicating reimbursement procedures across various regions. These financial hurdles restrict patient access to necessary care and limit market penetration in developing countries, where medical treatments are largely funded through out-of-pocket expenditures.

Market Driver

The increasing global incidence of skin cancers and melanoma serves as the main driver for growth in the diagnostics and therapeutics sector. Rising disease prevalence necessitates advanced screening techniques and effective pharmacological treatments, thereby expanding the patient population. With aging demographics and environmental factors driving higher case rates, healthcare systems are emphasizing early detection initiatives to lower mortality risks, which sustains the demand for diagnostic tools. As noted by the World Health Organization's International Agency for Research on Cancer in their February 2024 'Global cancer burden growing' release, roughly 330,000 new melanoma cases were diagnosed globally in 2022. This trend is particularly evident in high-risk areas; for example, Cancer Research UK's May 2024 analysis titled 'Skin cancer cases reach all-time high' projected a record 20,800 new melanoma diagnoses in the United Kingdom for 2024.

Simultaneously, the swift uptake of checkpoint inhibitors and novel immunotherapies is driving market revenue and transforming clinical protocols. The shift from conventional chemotherapy to precision immuno-oncology agents has enhanced survival rates, fostering broad commercial adoption of these biological therapies. Leading pharmaceutical companies are experiencing significant financial gains from these innovations, encouraging continued research and development in combination therapies. According to Merck's 'Fourth-Quarter and Full-Year 2023 Financial Results' from February 2024, Keytruda sales increased by 19% to $25.0 billion for the year, largely fueled by demand for metastatic indications such as melanoma. This financial success highlights the market's strong dependence on next-generation therapeutic categories to generate future value.

Market Challenge

The high costs linked to new therapeutic agents, specifically immunotherapies and biologics, serve as a major restraint on the Global Melanoma Diagnostics and Therapeutics Market. Although these treatments frequently offer superior clinical results, their steep pricing places considerable financial strain on private payers and healthcare systems. This economic pressure often results in strict reimbursement policies and extended approval periods for coverage, delaying the commercial uptake of these drugs in price-sensitive markets. As a result, the high financial barrier lowers prescription volumes, directly curbing revenue potential for pharmaceutical developers.

Global disparities in healthcare funding further aggravate this pricing issue, limiting the adoption of advanced therapies in areas dependent on out-of-pocket spending. According to the American Society of Clinical Oncology, the monthly cost for specific checkpoint inhibitors used for metastatic melanoma reached roughly $47,538 in 2024. These costs are unsustainable for numerous patients and smaller insurance plans, creating a significant divide between the availability of advanced therapeutics and their accessibility to the broader population, which ultimately stifles overall market growth.

Market Trends

The uptake of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapies marks a significant transition toward personalized cellular mechanisms for managing advanced, refractory solid tumors. This trend meets urgent needs for patients who have progressed after standard anti-PD-1 treatments, shifting focus from general immune stimulation to precise cellular targeting. The instant commercial success of the initial FDA-approved TIL product underscores the market's preparedness for complex biologics in treating metastatic disease. As reported in Iovance Biotherapeutics' 'Third Quarter and Year to Date 2024 Financial Results' from November 2024, the company achieved $42.1 million in net product revenue from U.S. sales of Amtagvi in the third quarter alone.

Concurrently, the creation of Personalized mRNA-Based Cancer Vaccines is transforming adjuvant care by employing neoantigen sequences to lower recurrence rates. Designed to identify the distinct mutational profile of a patient's tumor, these therapies elicit a robust and customized T-cell response when combined with proven checkpoint inhibitors. This strategy substantially improves long-term survival outlooks relative to standard monotherapies in post-surgical contexts. According to Merck's June 2024 announcement regarding 'Moderna and Merck Announce New 3-Year Data for mRNA-4157 Combined With Pembrolizumab', pairing the mRNA-4157 vaccine with Keytruda lowered the risk of death or recurrence by 49% compared to Keytruda monotherapy in high-risk stage III/IV melanoma patients.

Key Market Players

  • Abbott Laboratories Inc.
  • Amgen, Inc.
  • Bristol-Myers Squibb
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies Inc.
  • AstraZeneca Plc
  • Pfizer Inc.
  • Eli Lilly & Co.
  • GlaxoSmithKline Plc

Report Scope

In this report, the Global Melanoma Diagnostics and Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Melanoma Diagnostics and Therapeutics Market, By Product Type

  • Diagnostics Dermoscopy Devices
  • Biopsy Devices

Melanoma Diagnostics and Therapeutics Market, By Therapeutics

  • Chemotherapy
  • Biological Therapy
  • Targeted Therapy
  • Immune Therapy

Melanoma Diagnostics and Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Melanoma Diagnostics and Therapeutics Market.

Available Customizations:

Global Melanoma Diagnostics and Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Melanoma Diagnostics and Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Diagnostics Dermoscopy Devices, Biopsy Devices)
    • 5.2.2. By Therapeutics (Chemotherapy, Biological Therapy, Targeted Therapy, Immune Therapy)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Melanoma Diagnostics and Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Therapeutics
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Melanoma Diagnostics and Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Therapeutics
    • 6.3.2. Canada Melanoma Diagnostics and Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Therapeutics
    • 6.3.3. Mexico Melanoma Diagnostics and Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Therapeutics

7. Europe Melanoma Diagnostics and Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Therapeutics
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Melanoma Diagnostics and Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Therapeutics
    • 7.3.2. France Melanoma Diagnostics and Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Therapeutics
    • 7.3.3. United Kingdom Melanoma Diagnostics and Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Therapeutics
    • 7.3.4. Italy Melanoma Diagnostics and Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Therapeutics
    • 7.3.5. Spain Melanoma Diagnostics and Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Therapeutics

8. Asia Pacific Melanoma Diagnostics and Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Therapeutics
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Melanoma Diagnostics and Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Therapeutics
    • 8.3.2. India Melanoma Diagnostics and Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Therapeutics
    • 8.3.3. Japan Melanoma Diagnostics and Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Therapeutics
    • 8.3.4. South Korea Melanoma Diagnostics and Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Therapeutics
    • 8.3.5. Australia Melanoma Diagnostics and Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Therapeutics

9. Middle East & Africa Melanoma Diagnostics and Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Therapeutics
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Melanoma Diagnostics and Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Therapeutics
    • 9.3.2. UAE Melanoma Diagnostics and Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Therapeutics
    • 9.3.3. South Africa Melanoma Diagnostics and Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Therapeutics

10. South America Melanoma Diagnostics and Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Therapeutics
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Melanoma Diagnostics and Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Therapeutics
    • 10.3.2. Colombia Melanoma Diagnostics and Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Therapeutics
    • 10.3.3. Argentina Melanoma Diagnostics and Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Therapeutics

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Melanoma Diagnostics and Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amgen, Inc.
  • 15.3. Bristol-Myers Squibb
  • 15.4. Novartis AG
  • 15.5. F. Hoffmann-La Roche Ltd
  • 15.6. Agilent Technologies Inc.
  • 15.7. AstraZeneca Plc
  • 15.8. Pfizer Inc.
  • 15.9. Eli Lilly & Co.
  • 15.10. GlaxoSmithKline Plc

16. Strategic Recommendations

17. About Us & Disclaimer